WORLD’S CLINICAL LABORATORY NEWS LEADER ISSN 1068-1760
I
C
N
Vol. 39 No.2 • 4/2022
T
E
ELISA Blood Test for Heart Risk Prediction
R
N
A
T
I
O
DAILY CLINICAL LAB NEWS
®
N
‘Fingerprint’ Machine Learning Technique Identifies Various Bacteria in Seconds
ardiovascular disease (CVD) is the leading cause of death worldwide and a large proportion of these patients ultimately die from sudden cardiac death (SCD). Now, a new secretoneurin (SN) blood-based ELISA (enzyme-linked immunosorbent
S
ynergistic combination of surface-enhanced Raman spectroscopy and deep learning serves as an effective platform for separation-free detection of bacteria in arbitrary media. Researchers at the Korea Advanced Institute of Science and
Technology (KAIST, Daejeon, Korea; www.kaist.ac.kr) have demonstrated a quicker, more accurate process for bacterial identification which can take hours and often longer, despite time being precious when diagnosing infections and selecting appropriate
Cont’d on page 8
Cont’d on page 18
Groundbreaking DNA Test Profiles Biomarkers in Hundreds of Cancer-Relevant Genes
I
n lieu of conventional tests, a single diagnostic test can now evaluate biomarkers in 517 cancer-relevant genes across 30 types of solid tumors, thus enabling physicians to make precision medicine decisions for cancer patients.
Image: Cancer in the blood outbreak and treatment for malignant cells.
See article on page 4 V
I
S
I
T
LINKXPRESS COM
R E A D E R
S E R V I C E
®
P O R T A L
Renew/Start your Free Subscription Access Interactive Digital Magazine Instant Online Product Information: Identify LinkXpress codes of 1 interest as you read magazine ®
on LinkXpress.com 2 toClick reach reader service portal Mark code(s) of interest on 3 LinkXpress inquiry matrix ®
If your subscription is not renewed every 12 months your Free Subscription may be automatically discontinued
Hematology Analyzer Offers Integrated CBC and ESR Testing
raditionally, erythrocyte sedimentation rate (ESR) tests, T which measure how quickly red blood cells (RBCs) settle in diluted plasma over a specified period of time, are performed on an independent analyzer, and can take up to 60 minutes to get the results. Cont’d on page 22
Blood Test Predicts Likely Progression to Alzheimer’s Up to 6 Years in Advance
T
he first approved blood test can identify whether individuals with early cognitive impairment will or will not progress to Alzheimer’s disease with high accuracy. Diadem Srl (Brescia, Italy; www. diademdx.com) has received CE
V I S I T
IVD certification for its AlzoSure Predict prognostic blood test for the early prediction of Alzheimer’s disease, allowing the company to take the test to markets in the UK and the 27 countries of the European Union (EU). It also enables market Cont’d on page 8
A
L
Detecting Pancreatic Cancer in High-Risk Individuals
A
n immunoassay was able to detect pancreatic cancer in high-risk individuals and with high sensitivity and specificity. Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. A number of types of pancreatic cancer are known. Cont’d on page 20
Test Predicts Recurrence of Oropharynx Cancer
A
n extensive multi-institutional study demonstrates that a blood test to detect circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment. Results also indicate that the biomarker test may detect recurrent disease earlier than imaging or other standard methods of post-treatment surveillance, allowing physicians to Cont’d on page 10
INSIDE
COVID-19 Update. . . . . 5 Clinical News. . . . . . 4-24 IFCC News. . . . . . . . . . 25 Product News . . . . . 6-24 Events Calendar . . 30-31 PUBLISHED IN COOPERATION WITH
International Federation of Clinical Chemistry and Laboratory Medicine
GLOBETECH >>> MEDIA <<<